For now, Myriad wins in the volume of large, full of products, wide coverage, the company went public after the money is not bad; the strong point of the United States in the government relations and the ability to raise funds, after all, the backstage is not ordinary, but only on the product and R & D this piece of the inputs and the Myriad is not yet in the The company's main goal is to provide the best possible service to its customers.
In the field of guardianship and in vitro diagnostics, Myriad has already achieved the domestic No. 1, certain parameters and technology and Roche, Beckman and other foreign companies to compare has been comparable, and hospitals and distributors also recognized. The influence of the United States is still relatively low, the influence of the government signed a few large single, but the imaging products require deep technical precipitation, the current state-owned enterprises and the traditional GPS than the technical gap is large.
Now the national policy to support the domestic, I believe that whether the Myriad or the United States there is still a lot of room for growth. In the end, put aside the other only on the treatment of words, the United shadow than the Myriad more.
Research and development
Since its inception, Myriad has always taken "meeting customer needs" as the driving force for growth, and has gradually established an R&D management platform oriented to customer needs and centered on project management, so as to stay close to the market to fully understand the needs of the users and respond quickly to them, and provide the best service to global medical institutions by integrating innovative technologies and R&D. With the integration of innovative technology and R&D cost advantages, we are able to provide high performance-price ratio products and services to global medical institutions and create greater value for our customers.
Mediatech has established six R&D centers in Shenzhen, Beijing, Nanjing, Seattle, New Jersey and Stockholm. Nearly 30% of Myriad's employees work in the R&D system on a wide range of products with clinical applications.
Medera insists on investing about 10% of its annual turnover to support product innovation and R&D, and has established an R&D management platform that is in line with international standards.
Mediatech has an R&D management process that complies with CE, FDA standards and the ISO system. The development process is controlled and managed by an expert committee, and all products are designed in accordance with relevant international standards during the product development process, and comprehensive special tests (including EMC, safety, environmental, etc.) are conducted to validate that the safety and reliability of the products are adequately safeguarded.